- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06651190
Pain Caregiver Resource (PainCaRe)
Building mHealth Parent Capacity to Manage Pain in Young Children With Cancer: A Pilot Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Principal Investigator
- Phone Number: 206934 416-813-7654
- Email: lindsay.jibb@sickkids.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X8
- The Hospital for Sick Children
-
Contact:
- The Hospital for Sick Children Research Ethics Board
- Phone Number: 205718 416-813-7654
- Email: ask.crs@sickkids.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
- Be the primary caregiver, or person assuming the majority of care activities, for a child aged 2-11 years undergoing cancer treatment and experiencing above mild pain (≥3/10) in the week preceding study enrolment (pain measured by self or caregiver proxy using a validated numerical 11-point rating scale).
- Be able to speak and read English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Arm
Participants will download the PainCaRe app from the web to their personal phone either virtually or in-person. Parents will receive app-based notifications to complete a pain assessment report once-daily. Assessments not completed will be marked as "missed". Parents will also have the ability to complete ad hoc pain assessments as needed. In response to the assessment indicating a child has pain, evidence-based, algorithm-driven pharmacological, physical, or psychological pain treatment guidance will be provided. This guidance is tailored to the age and developmental stage of the child. |
The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home.
The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed.
Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents.
The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT.
Please find attached the study protocol for reference.
|
|
No Intervention: Control Arm
Parents randomized to the control arm (non-intervention group) will not be assigned to the PainCaRe app and their child will continue to receive standard medical and pain care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility - attrition
Time Frame: 1 year
|
Percent of caregivers not completing 8-week outcome measures.
Criteria for feasibility: attrition <25%.
|
1 year
|
|
Feasibility - accrual
Time Frame: 1 year
|
Percent of eligible caregivers accrued per recruitment day.
Criteria for feasibility: accrual >60%.
|
1 year
|
|
Feasibility - adherence
Time Frame: 8 weeks
|
Adherence to the intervention will be measured using the Analytics Platform to Evaluate Effective Engagement (APEEE) platform, a proprietary analytics software measuring the number of once-daily pain assessments completed and engagement with pain treatment guidance.
Criteria for feasibility: adherence to twice-daily pain reporting >65%.
|
8 weeks
|
|
Acceptability
Time Frame: 8 weeks
|
Measured with the Acceptability E-Scale (AES).
Criteria for acceptability: mean score of 4 on each item
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Child pain intensity - parent report
Time Frame: 8 weeks
|
Measured by caregiver proxy report using the Brief Pain Inventory
|
8 weeks
|
|
Child pain intensity - child report
Time Frame: 8 weeks
|
Measured by self-report for children ≥4 years of age using the Faces Pain Scale-Revised .
|
8 weeks
|
|
Child pain interference - parent report
Time Frame: 8 weeks
|
Measured by parent proxy for children <8 years of age using appropriate version of PROMIS Pediatric Scale
|
8 weeks
|
|
Child pain interference - child report
Time Frame: 8 weeks
|
Measured by self-report for children ≥8 years of age using appropriate version of PROMIS Pediatric Scale .
|
8 weeks
|
|
Child health-related quality of life - parent report
Time Frame: 8 weeks
|
Measured by self-report for children <8 years of age using appropriate versions of the Pediatric Quality of Life Inventory 4.0 .
|
8 weeks
|
|
Child health-related quality of life - child report
Time Frame: 8 weeks
|
Measured by self-report for children <8 years of age using appropriate versions of the Pediatric Quality of Life Inventory 4.0 .
|
8 weeks
|
|
Parent quality of life
Time Frame: 8 weeks
|
Measured by parent report using the Caregiver Quality of Life Index - Cancer .
|
8 weeks
|
|
Parent pain management self-efficacy
Time Frame: 8 weeks
|
Measured by parent report using the Pain Self-Efficacy Scale .
|
8 weeks
|
|
Parent care satisfaction
Time Frame: 8 weeks
|
Measured by parent report using the Satisfaction with Child Healthcare Survey .
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000081481
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.